231 related articles for article (PubMed ID: 20394038)
1. Should we measure C-reactive protein on earth or just on JUPITER?
Bajpai A; Goyal A; Sperling L
Clin Cardiol; 2010 Apr; 33(4):190-8. PubMed ID: 20394038
[TBL] [Abstract][Full Text] [Related]
2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
3. Jupiter to Earth: CRP promotes atherothrombosis.
Jialal I; Devaraj S
Metab Syndr Relat Disord; 2009 Feb; 7(1):1-3. PubMed ID: 19183073
[No Abstract] [Full Text] [Related]
4. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.
Kones R
Drug Des Devel Ther; 2010 Dec; 4():383-413. PubMed ID: 21267417
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin and the JUPITER trial: critical appraisal of a lifeless planet in the galaxy of primary prevention.
López A; Wright JM
Int J Occup Environ Health; 2012; 18(1):70-8. PubMed ID: 22550699
[TBL] [Abstract][Full Text] [Related]
6. The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences.
Narla V; Blaha MJ; Blumenthal RS; Michos ED
Vasc Health Risk Manag; 2009; 5():1033-42. PubMed ID: 20057896
[TBL] [Abstract][Full Text] [Related]
7. The role of C-reactive protein as a risk predictor of coronary atherosclerosis: implications from the JUPITER trial.
Abd TT; Eapen DJ; Bajpai A; Goyal A; Dollar A; Sperling L
Curr Atheroscler Rep; 2011 Apr; 13(2):154-61. PubMed ID: 21274757
[TBL] [Abstract][Full Text] [Related]
8. Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial.
Peña JM; Aspberg S; MacFadyen J; Glynn RJ; Solomon DH; Ridker PM
JAMA Intern Med; 2015 Feb; 175(2):171-7. PubMed ID: 25437881
[TBL] [Abstract][Full Text] [Related]
9. The JUPITER trial: How will it change clinical practice?
Watson KE
Rev Cardiovasc Med; 2009; 10(2):91-6. PubMed ID: 19593321
[TBL] [Abstract][Full Text] [Related]
10. Bringing JUPITER down to earth.
Després JP
Lancet; 2009 Apr; 373(9670):1147-8. PubMed ID: 19329179
[No Abstract] [Full Text] [Related]
11. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
O'Keefe JH; Carter MD; Lavie CJ; Bell DS
Postgrad Med; 2009 May; 121(3):113-8. PubMed ID: 19491548
[TBL] [Abstract][Full Text] [Related]
12. Low-risk older patients (50 years and older) with raised high-sensitivity CRP (hs-CRP) benefit from rosuvastatin therapy: the JUPITER study.
Cardiovasc J Afr; 2008; 19(6):332-4, discussion 335. PubMed ID: 19104734
[No Abstract] [Full Text] [Related]
13. Expanding the orbit of primary prevention--moving beyond JUPITER.
Hlatky MA
N Engl J Med; 2008 Nov; 359(21):2280-2. PubMed ID: 18997195
[No Abstract] [Full Text] [Related]
14. Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".
Vos E; Rose CP; Biron P
Circulation; 2010 Dec; 122(23):e576; author reply e577. PubMed ID: 21135369
[No Abstract] [Full Text] [Related]
15. Letter by Wells and Eisenberg regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".
Wells MT; Eisenberg T
Circulation; 2010 Dec; 122(23):e575; author reply e577. PubMed ID: 21135368
[No Abstract] [Full Text] [Related]
16. Is Jupiter also a god of primary prevention?
Accad M; Fred HL
Tex Heart Inst J; 2010; 37(1):6-7. PubMed ID: 20200621
[No Abstract] [Full Text] [Related]
17. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
Kones R
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.
Glynn RJ; Koenig W; Nordestgaard BG; Shepherd J; Ridker PM
Ann Intern Med; 2010 Apr; 152(8):488-96, W174. PubMed ID: 20404379
[TBL] [Abstract][Full Text] [Related]
19. [Statins in primary prophylaxis of cardiovascular diseases].
Kobalava ZhD; Villeval'de SV
Ter Arkh; 2011; 83(9):70-5. PubMed ID: 22145392
[TBL] [Abstract][Full Text] [Related]
20. Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
Shishehbor MH; Hazen SL
Cleve Clin J Med; 2009 Jan; 76(1):37-44. PubMed ID: 19122109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
